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cost-effective over rivaroxaban. ConClusions: In patients treated for acute pul-
monary embolism, dabigatran is a cost-effective alternative compared with both 
warfarin and rivaroxaban.
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objeCtives: To evaluate cost-effectiveness of the novel oral anticoagulant apixa-
ban compared to warfarin and aspirin in patients with NVAF from the Russian 
Federation national health care system perspective. Methods: Cost-effectiveness 
analysis was based on a Markov model that allowed estimation of the incremen-
tal cost-effectiveness ratio (ICER) for apixaban compared to warfarin and aspirin 
over lifetime horizon in vitamin K antagonists (VKA) suitable and VKA unsuitable 
patients with NVAF, respectively. The model enclosed cardiovascular event rates 
derived from the randomized clinical trials: ARISTOTLE and AVERROES. The fol-
lowing cardiovascular events were considered: ischemic and hemorrhagic stroke, 
intracranial hemorrhage, systemic embolism, other major bleeds, clinically rele-
vant non-major bleeds, myocardial infarction and cardiovascular hospitalizations. 
Characteristics of the baseline patients’ cohort including quality of INR control 
corresponded to the local population. Direct medical costs were determined based 
on the rates of the compulsory national medical insurance system. The price of 
the antithrombotic drugs was taken as a weighted average tender price in 2013. 
Cost-effectiveness threshold was set at 1,4 million rubles per quality-adjusted 
life year (QALY) gained and corresponded to the three times GDP per capita in 
the Russian Federation in 2013. One-way sensitivity analyses were undertaken to 
examine the effects of model drivers. Results: In the base case analysis it was 
demonstrated that apixaban compared to warfarin and aspirin provided additional 
0.187 and 0.214 QALYs, respectively. With that estimated ICER for apixaban com-
pared to warfarin and aspirin was 603.92 and 473.02 thousands rubles per QALY 
gained, respectively. Sensitivity analysis indicated that results were robust over 
explored range of inputs. ConClusions: According to the results of the modeling 
study apixaban may be considered as a cost-effective alternative to warfarin in 
VKA suitable patients and as a cost-effective alternative to aspirin in VKA unsuit-
able patients for NVAF treatment from the Russian Federation national health care 
system perspective.
PCV98
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objeCtives: This economic evaluation aimed to assess the cost-effectiveness of 
dabigatran compared with warfarin, in the treatment and secondary prevention 
of acute venous thromboembolism (VTE) comprising deep vein thrombosis (DVT) 
and pulmonary embolism (PE), in the UK health care setting, based on safety 
and efficacy data collected during pivotal phase III trials. Methods: A life-time 
Markov state-transition cohort model was developed around the two primary 
composite endpoints in the pivotal trials: recurrent VTE and VTE-related death 
(rVTE), and major or clinically relevant bleeding (MCRB). Intervention-specific 
probabilities of events within the composite endpoint rVTE (recurrent DVT; recur-
rent PE) and the composite endpoint MCRB (intracranial haemorrhage; other major 
bleeds; non-major bleeds) were sourced from the pivotal trials. Beyond the trials 
follow-up period, the probability of rVTE was sourced from the literature. Long-
term consequences of VTE were considered, namely chronic thromboembolic pul-
monary hypertension and post-thrombotic syndrome. The perspective on costs 
was that of the NHS and Public Social Services. Health outcomes were assessed 
in quality-adjusted life years (QALY). Utility values for health states and events 
were EQ-5D data collected within the clinical trials, and the published literature. 
Probabilistic sensitivity analyses (PSA) were undertaken. Results: In patients 
with index DVT, the estimated incremental cost-effectiveness ratio (ICER) of treat-
ment with dabigatran compared with warfarin was £614 per QALY gained; in 
patients with index PE, the ICER was £1,285/QALY; in the pooled DVT/PE group, the 
ICER was £862/QALY. In the treatment followed by secondary prevention analysis, 
ICER was £8,319/QALY. PSA suggested that the probability of dabigatran being 
cost-effective at a threshold of £30,000/QALY was 90%, 81% and 94% in acute 
treatment and 96% in secondary prevention respectively. ConClusions: In a 
UK setting, dabigatran appears to be a cost-effective option for treatment and 
secondary prevention of VTE in patients with acute DVT and acute PE compared 
with warfarin.
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objeCtives: The aim of the study was to compare the cost-utility of the two single-
pill triple combination antihypertensive therapies available in the Greek market 
for patients with moderate to severe hypertension; the valsartan (V) against the 
olmesartan (O) combination with amlodipine (A) and hydrochlorothiazide (H).  
Methods: A Markov model with eight health states was constructed. The short-
cost-effectiveness of surgery, endodermal ablation (ETA), ultrasound guided foam 
sclerotherapy (UGFS) and compression stockings (CS). The analysis was based on a 
Markov decision model, which was developed in consultation with members of the 
NICE guideline development group (GDG). The model had a five year time horizon, 
and took the perspective of the UK National Health Service. Clinical inputs were 
based on a network meta-analysis (NMA), informed by a systematic review of the 
clinical literature. Outcomes were expressed as costs and quality adjusted life years 
(QALYs). Results: All interventional treatments were found to be cost-effective 
compared to CS at a cost- effectiveness threshold of £20,000 per QALY gained. ETA 
was found to be the most cost-effective strategy overall, with an incremental cost-
effectiveness ratio of £3,161 per QALY gained compared to UGFS. Surgery and CS 
were dominated by ETA. ConClusions: Interventional treatment for VV is cost-
effective in the UK NHS. Specifically, based on current data, ETA is the most cost-
effective treatment in people for whom it is suitable. The results of this research 
were used to inform recommendations within the NICE guideline on VV. Funding: 
This work was undertaken by the National Clinical Guideline Centre, which received 
funding from the National Institute for Health and Clinical Excellence (NICE). The 
views expressed in this publication are those of the authors and not necessarily 
of the institute.
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objeCtives: Venous thromboembolism (VTE) including deep vein thrombosis 
(DVT) and pulmonary embolism (PE) is a common cardiovascular disorder. Acute 
VTE has been traditionally managed with short course parenteral anticoagulation 
followed by 3-6 months of a vitamin-K antagonist. Novel oral anticoagulants do 
not require routine coagulation monitoring and dose adjustment, thus potentially 
providing an alternative treatment option. The cost-effectiveness of dabigatran vs. 
rivaroxaban over a 6 months treatment course in the UK health care setting was 
evaluated in this research. Methods: A life-time Markov model was developed, 
encompassing recurrent VTE events and VTE-related deaths, and the most com-
mon adverse events during anticoagulation therapy: major or clinically relevant 
bleeds (MCRB). The model was populated with data from pooled RE-COVER and 
RE-COVER II dabigatran trials and the 6 months treatment duration subgroup of 
the rivaroxaban EINSTEIN-DVT and EINSTEIN-PE trials. Long-term consequences 
of VTE were considered. Costs were analysed from the NHS and Public Social 
Services perspectives. Health outcomes were assessed in quality-adjusted life 
years (QALY). Utility values for modelled health states were EQ-5D data from 
RE-COVER studies, and published data. Probabilistic sensitivity analyses (PSA) 
were undertaken. Results: In patients with index PE, 6 months treatment with 
dabigatran dominated treatment with rivaroxaban projecting less recurrent VTE 
and less MCRB at lower costs. Dabigatran was likely to remain cost-effective in 70% 
of cases at a threshold used in the UK of £30,000/QALY gained. Dabigatran contin-
ued to dominate treatment with rivaroxaban in patients with index DVT, project-
ing less non-fatal PE, less intra-cranial haemorrhages and less clinically relevant 
bleeds, but more recurrent DVT, with 68% likelihood of remaining cost-effective. 
In the pooled DVT/PE group, dabigatran dominated treatment with rivaroxaban 
and was 62% likely to remain cost-effective. ConClusions: Dabigatran is less 
costly and more effective than rivaroxaban when administered for 6 months after 
index PE, index DVT or both.
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objeCtives: This economic evaluation aimed to assess the cost-effectiveness 
of dabigatran etexilate for six months of treatment for acute pulmonary embo-
lism (PE) compared with warfarin and rivaroxaban in the UK health care set-
ting. Methods: A Markov state-transition cohort model was used to project the 
lifetime recurrence of PE and occurrence of deep vein thrombosis (DVT) in patients 
with initial acute PE. The incidence of recurrent venous thromboembolism (rVTE) 
was based on the relevant study endpoints of RE-COVER and RE-COVER II trials 
comparing dabigatran with warfarin, and the EINSTEIN-PE study for rivaroxaban. 
Intervention-specific probabilities of events within the composite efficacy end-
point and within the composite safety endpoint of major or clinically relevant 
bleeding (MCRB) were sourced from the very same randomised trials. Beyond 
the data from clinical studies, the probability of rVTE was sourced from the 
published literature. Long-term consequences of VTE were considered, namely 
chronic thromboembolic-induced pulmonary hypertension and post-thrombotic 
syndrome. The perspective on costs was that of the NHS and Public Social Services. 
Health outcomes were assessed in quality-adjusted life years (QALY). Utility val-
ues relevant to events and health staes were EQ-5D data from RE-COVER studies, 
and published literature. Probabilistic sensitivity analyses (PSA) were under-
taken. Results: Compared with warfarin, dabigatran projected similar number 
of rVTE, but was associated with less MCRB. The expected lifetime incremental 
cost-effectiveness ratios (ICERs) were £2,004/life years (LYs) and £1,285/QALYs. PSA 
showed 84% likelihood for dabigatran to remain cost-effective given a willingness-
to-pay of £30,000/QALY. When compared with rivaroxaban, treatment with dabi-
gatran was projected dominant,. Dabigatran projected less rVTE, less intracranial 
haemorrhages and clinical relevant non-major bleeds, but was associated with a 
higher risk of major bleeds. PSA showed 66% likelihood for dabigatran to remain 
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objeCtives: The objective of the present study was to assess efficiency of rehabili-
tation programs for patients after traumatic brain injury and acute cerebrovascular 
accident (stroke) in Russia. Methods: Short-term clinical and social outcomes 
(health status and disability rates) of rehabilitation were analyzed in the database 
of the Moscow Center of Speech Pathology and Neurological Rehabilitation. Changes 
in the officially registered disability rates and clinical outcomes were assessed for 3 
different strategies of rehabilitation: hospital, day care and home care. The decision 
tree model was constructed to simulate disability rates, direct and indirect costs of 
rehabilitation vs “no rehabilitation” scenario under conditions when officially regis-
tered disability corresponds to real health and functional status of patients. TreeAge 
Pro 2009 and Microsoft Excel 2010 software were used for modeling. Results: Use 
of officially registered disability as an endpoint does not reflect the actual effective-
ness of rehabilitation programs. 90% of patients are able to live without assistance 
after discharge but still are registered as 1stdegree disabled (most severe degree of 
disability in Russia) in order to receive social benefits. According to preliminary 
results of modeling total cost of rehabilitation may be less than cost of ”no reha-
bilitation” scenario if disability correlates with actual health and functional status 
of individuals, for example annual total cost is € 25,923 for home care rehabilita-
tion and € 28,124 for “no rehabilitation” scenario. ConClusions: It’s necessary to 
improve approaches to official disability registration in Russia in order to make 
rehabilitation programs efficient.
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objeCtives: We aimed at estimating and comparing the total management costs of 
patients admitted to the emergency department (ED) with recent (< 48 hours) atrial 
fibrillation (AF) between three types of cardioversion: direct current cardioversion 
(DCC), intravenous amiodarone or intravenous vernakalant. Methods: A decision 
analytic model was developed to mimic the pathways of patients admitted via the 
ED with recent AF and to calculate an average AF management cost per strategy. 
The cardioversion success rates were based on published observational studies 
(DCC 90%, amiodarone 68%, vernakalant 70%). In case of successful conversion 
the patient was released directly from the ED to home (DCC 50%, amiodarone 25%, 
vernakalant 100%) or admitted to the hospital for a median of 1 day (DCC) or 2 
days (amiodarone) reflecting cardioversion-specific times to sinus rhythm. After 
a failed pharmacological cardioversion, patients were assumed to receive a DCC; 
failed DCC was followed by intravenous amiodarone. The associated inpatient costs 
were retrieved from the IMS Hospital Disease Database (HDD2011). ED treatments 
were costed using the national health care payer tariffs. Univariate and probabilistic 
sensitivity analyses were performed. Results: The total AF management costs 
from ED to discharge were estimated at € 952 (DCC), € 1,894 (amiodarone) and € 1.354 
(vernakalant). Given the relative frequencies of amiodarone (55%) and DCC (45%) to 
treat recent FA in Belgian ED, the weighted average management cost was € 1.470 
(+ € 116/treatment vs. vernakalant). The break-even situation is reached when 75% 
of successfully treated vernakalant patients avoid the hospitalization (base case 
100%). Based on a probabilistic sensitivity analysis, vernakalant was cost saving in 
55% of the 1,000 simulations vs. current management. ConClusions: In patients 
with recent AF, the rapid mode of action of vernakalant increases the chance of 
obtaining sinus rhythm within 48 hours, and its use was cost saving compared to 
the current average Belgian practice.
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objeCtives: Demonstrate the cost savings of using the GORE® PROPATEN® Vascular 
Graft compared to standard ePTFE vascular grafts in the management of PAD 
patients. Superior clinical outcomes in terms of primary / secondary patency and 
limb salvage rates result in lower average per-patient treatment costs. Background: 
Vascular bypass is used in patients with PAD (Peripheral Arterial Disease) to treat 
ischemic rest pain, to improve walking distance in patients with severe life-limiting 
claudication, and to save limbs that might otherwise require amputation. When 
patients presenting for peripheral artery reconstruction have absent or inadequate 
saphenous veins due to prior use, small size, or poor quality, vascular surgeons 
may choose a prosthetic bypass graft. The GORE® PROPATEN® Vascular Graft fea-
tures a proprietary end-point covalent linkage of heparin molecules to the luminal 
surface of the graft that provides sustained resistance to thrombosis. Methods: 
A cost model analysis was developed to represent hospital treatment costs. A typical 
PAD patient’s treatment pathway in Spanish clinical practice was identified by a 
survey involving Spanish vascular surgeons. A literature review was conducted to 
determine patency and limb salvage rates. Spanish GRD AP27–2012-Ministerio de 
Sanidad tariffs were used as hospital cost of treatment inputs. A three-year patient 
management cycle was considered. Results: Better patency and limb salvage rates 
obtained using the GORE® PROPATEN® Vascular Graft result in fewer reinterven-
tions and amputations, corresponding to lower per-patient treatment costs. The 
cost model demonstrates an overall cost saving for PAD patient management using 
the GORE® PROPATEN® Vascular Graft for infrapopliteal bypass. The cumulative 
term effect of antihypertensive treatment on blood pressure was extracted from 
relative clinical trials and these data were extrapolated through the Hellenic SCORE 
and Framingham risk equations, estimating the long-term survival and quality-
adjusted life-years (QALYs) gained. Costs and outcomes were evaluated over life-
time, divided into annual cycles and were discounted at 3.0% with 2014 as reference 
year. The analysis was conducted from the Greek third-party-payer perspective 
(EOPYY). Results: The total lifetime cost related to V/A/H combination was esti-
mated to be lower (€ 10,970) compared to that of the O/A/H combination (€ 11,080), 
despite the higher drug acquisition cost. Moreover, the estimated QALYs gained with 
the V/A/H combination were 10.88 vs. 10.80 for O/A/H combination. Therefore, the 
V/A/H combination was found to be a dominant alternative over O/A/H combina-
tion, as it was associated with lower cost and greater efficacy. In a scenario when 
the ambulatory blood pressure measurements were taken into account, the ICER 
was far lower than the Greek GDP per capita (€ 6,845/QALY) vs. O/A/H combination, 
suggesting V/A/H combination to be a cost-effective choice. Extensive sensitiv-
ity analyses confirmed the robustness of the results. The probabilistic sensitivity 
analysis also demonstrated that there was about 80% probability for the V/A/H 
triple combination to be cost-effective at a willingness-to-pay threshold of € 16,000/
QALY. ConClusions: This is the first study performed to compare the cost-utility 
of the two single-pill triple antihypertensive therapies. The V/A/H combination was 
proven dominant over the O/A/H combination for the treatment of moderate to 
severe hypertension.
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objeCtives: To assess cost-effectiveness of high sensitivity troponin (hs-cTn) 
assays for the management of adults presenting with acute chest pain at the 
emergency department. Methods: An economic model was constructed to esti-
mate lifetime costs and QALYs of five hs-cTn strategies (differing according to 
manufacturer, timing of the test, number of tests and cutoff point for a positive 
test result) compared to standard troponin (sTn) testing at presentation and at 
10-12 hours, which was considered the reference standard. In the base case, it 
was assumed that sTn testing had perfect accuracy for diagnosing AMI and only 
patients with a positive test for sTn were at increased risk for adverse events and 
would benefit from immediate treatment. In a secondary analysis, a proportion 
of patients with a positive hs-cTn test and a negative sTn test were at increased 
risk for adverse events and would benefit from immediate treatment. Results: 
Base case: Strategies considered cost-effective depending upon ICER thresholds 
were Abbott ARCHITECT hs-cTnI 99th centile (thresholds < £6,597), Beckman 
Coulter hs-cTnI 99th centile (thresholds £6,597 - £30,042), Abbott ARCHITECT hs-
cTnI optimal strategy (thresholds £30,042 - £103,194), and the sTn test (thresholds 
> £103,194). Secondary analysis: Strategies considered cost-effective were Abbott 
ARCHITECT hs-cTnI 99th centile (< £12,217), Roche Elecsys hs-cTnT 99th centile 
(£12,217 - £14,992) and Abbott ARCHITECT hs-cTnI optimal strategy (> £14,992). 
STn was dominated. Sensitivity/subgroup analyses: Main drivers are: the differ-
ence in outcomes between treated and untreated patients, and treatment costs 
for patients testing false-positive. Hs-cTn testing is more cost-effective in younger 
age, pre-existing coronary artery disease, and symptom onset < 3hrs ago. No test-
ing is only cost-effective when pre-test prevalence is 1%. ConClusions: There 
is no strong evidence to prefer one hs-cTn testing strategy over another. Results 
do indicate that hs-cTn testing in general may be cost-effective compared to sTn 
testing, especially in the secondary analysis.
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objeCtives: Recent studies have demonstrated the safety and efficacy of cath-
eter-based renal denervation (RDN) for the treatment of resistant hypertension. 
These studies have been used to estimate the cost effectiveness of this approach, 
however, there is no such published estimation in the Dutch health care setting. 
We aimed to determine the cost effectiveness of RDN from the perspective of 
the health care payer in The Netherlands. Methods: A Markov state-transition 
model previously constructed in TreeAge® was adapted to Microsoft Excel®. The 
Excel-based model was updated with costs and quality-adjusted life years (QALYs) 
relevant to the Dutch setting and the cost effectiveness of RDN was compared 
with standard of care (SoC) for patients with resistant hypertension. The effi-
cacy of RDN treatment was modelled as a reduction in the risk of cardiovascular 
events associated with a lower systolic blood pressure (SBP). Results: Base case 
deterministic results showed that treatment with RDN resulted in an increase in 
QALYs of 0.89 at an incremental cost of € 1,315 per patient resulting in an ICER of 
just € 1,474 Deterministic and probabilistic sensitivity analyses (PSA) indicated 
treatment with RDN therapy was cost effective at conventional willingness-to-
pay thresholds used in The Netherlands of € 10,000–80,000 per QALY. Furthermore, 
9.5% of PSA iterations showed RDN to be a cost saving treatment compared to 
SoC. ConClusions: RDN is a cost-effective intervention for patients with resist-
ant hypertension in The Netherlands.
